Esperion Therapeutics (ESPR): Pivotal Bempedoic Acid Program Fully Underway - Needham

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Esperion Therapeutics (ESPR): Pivotal Bempedoic Acid Program Fully Underway - Needham

Esperion Therapeutics (ESPR) Initiates CVOT Trial for Bempedoic Acid

January 9, 2017 8:08 AM EST

Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced the initiation of the global cardiovascular outcomes trial (CVOT) to assess the effects of bempedoic acid on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease (CVD) who are only able to tolerate less than the lowest approved daily starting dose of a statin and considered statin intolerant.

The CVOT known as Cholesterol Lowering via... More